Free Republic
Browse · Search
News/Activism
Topics · Post Article

To: Coleus; grey_whiskers; BIGLOOK; Peach; airborne; Asphalt; Dr. Scarpetta; I'm ALL Right!; ...
I withdraw the prediction of a Nobel prize, although it's a very interesting piece of work. There's no mention of immunoprivileged status in the abstract.

Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.

It's a lentivirus method of gene therapy. Sixty two percent of the mice had no response or worse, i.e. graft versus host disease or host versus graft disease. Cancer patients are already considered immunocompromised. Any requirement for immunosuppressant drugs would increase morbidity and mortality, IMHO.

16 posted on 05/20/2009 10:20:12 AM PDT by neverdem (Xin loi minh oi)
[ Post Reply | Private Reply | To 3 | View Replies ]


To: neverdem
look at this: PVCT

Rose Bengal ......Target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. Clinical trials for metastatic melanoma and recurrent breast carcinoma are currently underway.

Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method)

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)", will be presented on June 1, 2009 in the 8:00 a.m. - 12:00 p.m. General Poster Session (Group F, Brd. F15), at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program at the Orange County Convention Center in Orlando, Florida.

Dr. Sanjiv S. Agarwala, Principal Investigator for Provectus' Phase 2 PV-10 trial site at St. Luke's Hospital & Health Network in Bethlehem, PA will present an update on the development efforts with PV-10 for metastatic melanoma, including interim Phase 2 safety and efficacy data on the first 40 subjects in the trial and interim bystander correlation data on response of untreated tumors in subjects whose treated tumors responded successfully. Additional Phase 1 survival data will also be presented.

.

18 posted on 05/21/2009 1:24:24 AM PDT by Elle Bee
[ Post Reply | Private Reply | To 16 | View Replies ]

Free Republic
Browse · Search
News/Activism
Topics · Post Article


FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson